Trial Profile
A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Nov 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal oedema
- Focus Registrational; Therapeutic Use
- Acronyms GALILEO
- Sponsors Bayer; Bayer HealthCare; Regeneron Pharmaceuticals
- 28 Nov 2022 Results of post hoc analysis of studies(COPERNICUS and GALILEO trials for CRVO and VIBRANT trial) assessing Correlation between change in central subfield thickness and change in visual acuity in macular edema due to retinal vein occlusion published in the Graefes Archive for Clinical and Experimental Ophthalmology
- 12 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 12 Nov 2013 New trial record